{"id":"lomerizine","rwe":[],"tags":[{"label":"lomerizine","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Voltage-dependent N-type calcium channel subunit alpha-1B","category":"target"},{"label":"CACNA1B","category":"gene"},{"label":"Active","category":"status"},{"label":"Calcium Channel Blockers","category":"pharmacology"},{"label":"Calcium-Regulating Hormones and Agents","category":"pharmacology"},{"label":"Cardiovascular Agents","category":"pharmacology"},{"label":"Membrane Transport Modulators","category":"pharmacology"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":["lomerizine dihydrochloride","lomerizine","lomerizine hydrochloride","lomerizine HCl"],"offLabel":[],"synonyms":["lomerizine dihydrochloride","lomerizine","lomerizine hydrochloride","lomerizine HCl"],"timeline":[],"aiSummary":"Lomerizine is a small molecule drug that targets the voltage-dependent N-type calcium channel subunit alpha-1B. It is classified as a lomerizine, but its commercial status and approved indications are unknown. The mechanism of action involves blocking calcium channels to reduce neuronal excitability. As a result, lomerizine may be used to treat conditions characterized by excessive neuronal activity. However, its development and approval status are unclear.","approvals":[],"ecosystem":[],"mechanism":{"target":"Voltage-dependent N-type calcium channel subunit alpha-1B","targets":[{"gene":"CACNA1B","source":"DrugCentral","target":"Voltage-dependent N-type calcium channel subunit alpha-1B","protein":"Voltage-dependent N-type calcium channel subunit alpha-1B"}],"modality":"Small Molecule","drugClass":"lomerizine","explanation":"Imagine your brain cells are like a group of excited kids in a classroom. They're all talking and moving around, making it hard to focus. Lomerizine helps calm them down by blocking the 'doors' that let calcium ions flow in, which helps reduce the noise and chaos.","oneSentence":"Lomerizine works by blocking calcium channels in the brain to reduce excessive neuronal activity.","technicalDetail":"Lomerizine acts as a selective blocker of the voltage-dependent N-type calcium channel subunit alpha-1B, thereby reducing the influx of calcium ions into neurons and modulating neuronal excitability."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1595","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=LOMERIZINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T12:23:33.595468","biosimilars":[],"competitors":[{"drugName":"amitriptyline","drugSlug":"amitriptyline","fdaApproval":"1961-04-07","genericCount":33,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"amoxapine","drugSlug":"amoxapine","fdaApproval":"1980-09-22","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"clomipramine","drugSlug":"clomipramine","fdaApproval":"1989-12-29","genericCount":19,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"cyclobenzaprine","drugSlug":"cyclobenzaprine","fdaApproval":"1977-08-26","patentExpiry":"Mar 14, 2034","patentStatus":"Patent protected","relationship":"same-target"},{"drugName":"desipramine","drugSlug":"desipramine","fdaApproval":"1964-11-20","genericCount":8,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"imipramine","drugSlug":"imipramine","fdaApproval":"1959-04-16","genericCount":3,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"maprotiline","drugSlug":"maprotiline","fdaApproval":"1980-12-01","genericCount":4,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"mibefradil","drugSlug":"mibefradil","fdaApproval":"1997-08-01","relationship":"same-target"},{"drugName":"nortriptyline","drugSlug":"nortriptyline","fdaApproval":"1964-11-06","genericCount":9,"patentStatus":"Off-patent — generic available","relationship":"same-target"},{"drugName":"promethazine","drugSlug":"promethazine","fdaApproval":"1951-03-29","genericCount":48,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"dataSources":[{"url":"https://drugcentral.org","name":"DrugCentral","fields":["indications","contraindications","safety","target","drugInteractions"],"retrievedDate":"2026-04-07"}],"genericName":"lomerizine","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"amitriptyline","brandName":"amitriptyline","genericName":"amitriptyline","approvalYear":"1961","relationship":"same-target"},{"drugId":"amoxapine","brandName":"amoxapine","genericName":"amoxapine","approvalYear":"1980","relationship":"same-target"},{"drugId":"clomipramine","brandName":"clomipramine","genericName":"clomipramine","approvalYear":"1989","relationship":"same-target"},{"drugId":"cyclobenzaprine","brandName":"cyclobenzaprine","genericName":"cyclobenzaprine","approvalYear":"1977","relationship":"same-target"},{"drugId":"desipramine","brandName":"desipramine","genericName":"desipramine","approvalYear":"1964","relationship":"same-target"},{"drugId":"imipramine","brandName":"imipramine","genericName":"imipramine","approvalYear":"1959","relationship":"same-target"},{"drugId":"maprotiline","brandName":"maprotiline","genericName":"maprotiline","approvalYear":"1980","relationship":"same-target"},{"drugId":"mibefradil","brandName":"mibefradil","genericName":"mibefradil","approvalYear":"1997","relationship":"same-target"},{"drugId":"nortriptyline","brandName":"nortriptyline","genericName":"nortriptyline","approvalYear":"1964","relationship":"same-target"},{"drugId":"promethazine","brandName":"promethazine","genericName":"promethazine","approvalYear":"1951","relationship":"same-target"}],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{},"crossReferences":{"UNII":"DEE37CY4VO","CHEBI":"CHEBI:94682","INN_ID":"7004","UMLSCUI":"C0630704","ChEMBL_ID":"CHEMBL29188","KEGG_DRUG":"D02633","DRUGBANK_ID":"DB14065","PUBCHEM_CID":"3949","SECONDARY_CAS_RN":"101477-54-7","MESH_SUPPLEMENTAL_RECORD_UI":"C052424"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":101,"therapeuticAreas":["Neuroscience"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"LOMERIZINE","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}